Uzbekistan vs Vanuatu: Statin use vs. average non-HDL cholesterol levels
Uzbekistan
3.6
in 2018
Vanuatu
3.6
in 2018
Uzbekistan rank
30th
Vanuatu rank
30th
Statin use vs. average non-HDL cholesterol levels over time
- Uzbekistan
- Vanuatu
How they compare
Uzbekistan currently reports 3.6 against 3.6 in Vanuatu, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Uzbekistan ahead.
Uzbekistan ranks 30th and Vanuatu ranks 30th of 191 countries.
Across the 4 decades both report, Uzbekistan averaged higher in 1 and Vanuatu in 3.
Head to head by decade
| Decade | Uzbekistan | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.32 | 3.32 | 0 | Uzbekistan |
| 1990s | 3.15 | 3.47 | 0.32 | Vanuatu |
| 2000s | 3.19 | 3.52 | 0.33 | Vanuatu |
| 2010s | 3.46 | 3.6 | 0.1444 | Vanuatu |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Uzbekistan or Vanuatu?
- Uzbekistan, at 3.6 against 3.6 in Vanuatu as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Uzbekistan and Vanuatu?
- 0, with Uzbekistan ahead.
- How many years of comparable data are there for Uzbekistan and Vanuatu?
- 39 years are reported by both, from 1980 to 2018.
- How do Uzbekistan and Vanuatu rank globally for statin use vs. average non-hdl cholesterol levels?
- Uzbekistan ranks 30th and Vanuatu ranks 30th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.